Lenire is now available from HØR AS, Norway’s largest private provider of tinnitus care
Lenire®, the treatment device shown to reduce tinnitus symptoms in 86.2% of patients, is now available in Norway. Neuromod Devices has reached an agreement with HØR AS, Norway’s largest private provider of hearing and tinnitus care, to make its Lenire tinnitus treatment device available in Norway.
Tinnitus, commonly known as “ringing in the ears”, is a complex neurological condition resulting in the perception of sound without an external source. It’s thought to affect 10-15% of the adult population globallyi which could mean up to 650,000 Norwegians are living with the condition.
Through this agreement, HØR’s specialist audiology team has licence from Neuromod to provide Lenire for the treatment of tinnitus to suitable patients in their chain of private clinics throughout Norway. HØR’s flagship clinic is at Ullevål Stadion, with an additional inhouse clinic at Aleris Frogner. The organisation is expanding with two more clinics in Trondheim and Vestfold opening in the coming months.
“I’m delighted that by working with HØR we can make Lenire available to people living with tinnitus in Norway. Tinnitus remains a significant healthcare challenge but by partnering with clinical specialists like the team at HØR we can improve patient outcomes for people living with the condition,” explains Dr Ross O’Neill, Founder and CEO of Neuromod Devices.
The agreement comes following Lenire’s launch in Spain in early 2022 and the publication of an independent real-world study demonstrating the safety and efficacy of the Lenire device for improving symptoms in tinnitus patients. The study found that 85% of tinnitus patients experienced a reduction in their tinnitus symptoms, as measured by THIii, following six to 12 weeks of treatment using Lenireiii. The results were recently published in the highly ranked scientific journal, Brain Stimulation.
“I’m delighted that HØR are partnering with Lenire so we can provide an evidence-based treatment option that has seen encouraging patient outcomes in large-scale clinical trials and in the real world. I’m looking forward to working with Neuromod closely as we open our new clinics in Trondheim and Vestfold so we can provide care to more people who are living with tinnitus,” explains Janne Hallset Mykkelbost, CEO at HØR.
Norway is the latest country that Lenire is available in following significant expansion of the device’s availability throughout Europe, including the UK, Spain, Switzerland, and Austria. Find out where Lenire is available using our clinical map.
References
(i) Baguely et al., Tinnitus, The Lancet (2013), https://www.sciencedirect.com/science/article/pii/S0140673613601427
(ii) THI or Tinnitus Handicap Inventory is a clinical standard for measuring the impact of tinnitus on someone’s day-to-day life. Measured on a scale of 100, the higher the score, the greater the impact of tinnitus. Reducing a person’s THI score should correspond to improved quality of life by reducing how their tinnitus is affecting them.
(iii) Buechner A, Lesinski-Schiedat A, Becker P, Lenarz T, Real-world clinical experience with bimodal neuromodulation for the treatment of tinnitus – A case series, Brain Stimulation (2022), doi: https://doi.org/10.1016/j.brs.2022.01.022. (v) Conlon et al., Sci. Transl. Med. 12, eabb2830 (2020)
